Clinical trials: Inflammatory Myelopathies
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
Antibody-mediated inflammatory diseases of the nervous system (also known as autoimmune diseases of the nervous system) are autoimmune diseases in which autoimmune cells and immune molecules attack the nervous system as the main…
- Conditions
- Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder, Myasthenia Gravis
- Trial name
- CARTinNS (NCT04561557)
- Testing
- CT103A cells, Cyclophosphamide and fludarabine
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tongji Hospital
Poliomyelitis
The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains(Sabin IPV)
Based on pre-clinical trial and phase 1 and phase 2 clinical data and principle of GCP, the objective of phase Ⅲ clinical trial is to evaluate safety and immunogenicity of Inactivated Poliomyelitis Vaccine made from Sabin…
- Trial name
- IPV (NCT01510366)
- Testing
- Inactivated Poliomyelitis Vaccine (Sabin strains), Inactivated Poliomyelitis Vaccine (Salk strains)
- Where
- 2 sites in China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Institute of Medical Biology, Chinese Academy of Medical Sciences
HTLV-1 Infection, HTLV I Associated Myelopathies
Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection
This phase 2b, open-label, randomized controlled trial evaluates the efficacy and safety of dolutegravir (DTG) alone versus dolutegravir combined with tenofovir disoproxil fumarate (TDF) in individuals with HTLV-1 infection and…
- Conditions
- HTLV-1 Infection, HTLV I Associated Myelopathies, HTLV I Associated T Cell Leukemia Lymphoma, Neuritis
- Trial name
- DOT-H (NCT07555431)
- Testing
- Combination of Dolutegravir + Tenofovir DF for treatment of HTLV-1 infection, Dolutegravir (DTG)
- Where
- Brazil
- Volunteers
- 146 people
- Sponsor
- Carlos Brites
NMO Spectrum Disorder, MRI
Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
CLUE is a prospective study to assess structural and functional changes of the brain, spinal cord, and optic nerve, as well as the inflammatory environment in patients with neuroinflammatory and demyelinating diseases.
- Conditions
- NMO Spectrum Disorder, MRI, Multiple Sclerosis, MOGAD
- Trial name
- NCT04106830
- Testing
- Intravenous steroid
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Beijing Tiantan Hospital
Poliomyelitis
Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 Months
This is a phase III assessing the safety and immunogenicity of adjuvanted the reduced dose inactivated polio vaccine, IPV-Al SSI given as a booster vaccination to infants who were previously immunised with primary vaccination of…
- Trial name
- NCT03671616
- Testing
- IPV-Al SSI
- Where
- Panama
- Volunteers
- 666 people, healthy volunteers welcome
- Sponsor
- Statens Serum Institut
Neuromyelitis Optica Spectrum Disorders
An Open Label Study of the Effects of SHR1459 in NMOSDs Patients
This is an open-label study, to evaluate the efficacy and safety of SHR1459 in participants with NMOSDs.
- Trial name
- NCT04670770
- Testing
- Drug - SHR1459
- Where
- 8 sites in China
- Volunteers
- 10 people
- Sponsor
- Reistone Biopharma Company Limited
Poliomyelitis
Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine
The goal of this study is to compare the immunogenicity and safety of sIPV administered via subcutaneous and intramuscular injection routes
- Trial name
- NCT07457060
- Testing
- 2wIPV+1sIPV, 1wIPV+2sIPV, 3wIPV
- Where
- 3 sites in Philippines
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Diphtheria, Tetanus
Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months
As per request by the Heath Authorities, the present clinical study will assess the immunogenicity and safety of sanofi pasteur's DTacP-IPV// PRP~T combined vaccine (PENTAXIM™) as a three-dose primary vaccination at 2, 3, and 4…
- Conditions
- Diphtheria, Tetanus, Haemophilus Influenzae Type b, Pertussis
- Trial name
- NCT00453570
- Testing
- Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib, Diphtheria, Tetanus, & Acellular Pertussis Combined, Absorbed
- Where
- China
- Volunteers
- 792 people, healthy volunteers welcome
- Sponsor
- Sanofi
Post-polio Syndrome
Spinal Cord Gray Matter Imaging in Post Polio Syndrome
This is a longitudinal, observational study with the aims of comparing spinal cord gray matter areas in patients with Post-Polio Syndrome to age and sex matched healthy control subjects and to correlate atrophy with metrics of…
- Trial name
- NCT03561623
- Testing
- magnetic resonance (MR) Imaging, quantitative muscle force assessment
- Where
- Switzerland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Haemophilus Influenzae Type b, Acellular Pertussis
Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib)
This study will evaluate the safety and reactogenicity of Infanrix-IPV/Hib given as a three-dose primary vaccination course to healthy infants at 2-3-4 or 3-4-5 months of age.
- Conditions
- Haemophilus Influenzae Type b, Acellular Pertussis, Diphtheria, Tetanus
- Trial name
- NCT00964028
- Testing
- Infanrix™-IPV/Hib
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Optic Neuritis, Neuromyelitis Optica
Optic Neuritis Differential Diagnosis Study
Background: Optic neuritis is a frequent cause of vision loss encountered by ophthalmologists in the Caribbean. The diagnosis is made on clinical grounds.
- Conditions
- Optic Neuritis, Neuromyelitis Optica, Multiple Sclerosis
- Trial name
- ONDDS (NCT03370965)
- Testing
- Neuro-ophtalmology examination
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital Center of Martinique
Poliomyelitis
IPV Clinical Trial - The Gambia
The overall goal of this study is to identify interference between intramuscular Inactivated Polio Vaccine (IPV) and other vaccines (Measles Rubella and Yellow Fever) co-administered at nine months of age and to confirm the…
- Trial name
- IPV (NCT01847872)
- Testing
- IPV IM Needle, IPV ID Needle, IPV IM Device
- Where
- The Gambia
- Volunteers
- 1,504 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Antibody-mediated Rejection, NMO Spectrum Disorder
Biorepository and Registry for Plasma Exchange Patients
Patients who have immune mediated diseases commonly undergo plasma exchange (PLEX) procedures to remove pathological substances, typically believed to be antibodies.
- Conditions
- Antibody-mediated Rejection, NMO Spectrum Disorder, TTP, CIDP
- Trial name
- NCT05004493
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Charles M Knudson
Spinal Cord Injuries, Multiple Sclerosis
AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis
The UAB Institute for Arts In Medicine (AIM) is currently implementing an expressive emotional writing pilot project for adults with paralysis caused by neurological conditions such as traumatic head or spinal cord injury.
- Conditions
- Spinal Cord Injuries, Multiple Sclerosis, Transverse Myelitis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT04721717
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Poliomyelitis
Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine
This is an open-label phase IV, randomized controlled trial of mOPV2 alone and mOPV2 along with IPV. This trial will assess the impact on type 2 immunogenicity by reducing the interval between mOPV2 doses.
- Trial name
- NCT02643368
- Testing
- mOPV2 at 6 and 7 weeks of age, mOPV2 at 6 and 8 weeks of age, mOPV2 at 6 and 10 weeks of age
- Where
- Bangladesh
- Volunteers
- 760 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Post-Poliomyélitis Syndrom
Treatment of Post-poliomyelitis Syndrome by Intravenous Immunoglobulin
Our study evaluates the efficacy of IGIV treatment in PPS on clinical (walking and pain) and isokinetic (muscle strength) criteria, on patients with PS at Montpellier's Hospital
- Trial name
- PPS and IGIV (NCT04004390)
- Where
- France
- Volunteers
- 17 people
- Sponsor
- University Hospital, Montpellier
Neuromyelitis Optica Spectrum Disorder
Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder
The purpose of this proof of concept study is to assess the acceptability and safety of MR-C-014 in persons with Neuromyelitis optica spectrum disorder (NMOSD) who have a gait deficit.
- Trial name
- aNiMatO (NCT06374264)
- Testing
- MR-C-014
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- MedRhythms, Inc.
Acute Flaccid Paralysis, AFP
Pattern of AFP in Chhidren Admitted at Sohag University Hospital
This study is observational study aims to study the Clinical profile, Possible risk factors and Outcome of Acute flaccid paralysis in children at Sohag University Hospital.
- Conditions
- Acute Flaccid Paralysis, AFP, Gullian Barre Syndrome, Transverse Myelitis
- Trial name
- AFP-SUH (NCT07775066)
- Testing
- Observitional follow-up
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Mohamed Aboelhamd Ali
Transverse Myelitis, Neuromyelitis Optica
Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)
Transverse myelitis (TM) is an inflammatory disorder of the spinal cord that leads to disabilities of gait. Dalfampridine, a sustained-release potassium inhibitor has been shown to be effective in improving gait and other…
- Conditions
- Transverse Myelitis, Neuromyelitis Optica, Idiopathic Transverse Myelitis, Myelitis NOS
- Trial name
- NCT02166346
- Testing
- Dalfampridine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Johns Hopkins University
Neuromyelitis Optica, Devic's Disease
Autologous Transplant To End NMO Spectrum Disorder
This study is designed to treat your disease with an autologous stem cell transplant using a regimen of immune suppressant drugs and chemotherapy to reset your immune system and to determine if your disease will go into long-term…
- Conditions
- Neuromyelitis Optica, Devic's Disease, NMO Spectrum Disorder
- Trial name
- ATTEND (NCT03829566)
- Testing
- Rituximab, Cyclophosphamide, Mesna
- Where
- 2 sites in United States
- Sponsor
- Northwestern University